Artiva Biotherapeutics, Inc.ARTVNASDAQ
Loading
Year-over-year research & development expense growth
3Y CAGR
+117.5%/yr
Annual compound
Percentile
P83
Within normal range
vs 3Y Ago
10.3x
Strong expansion
Streak
1 yr
Consecutive growthStable
| Period | Value |
|---|---|
| 2025 | 38.17% |
| 2024 | 0.15% |
| 2023 | 14.25% |
| 2022 | 3.71% |
| 2021 | 206.32% |
| 2020 | 0.00% |
| 2019 | 0.00% |